GardenSpider
Well-known member
The nasal spray vaccine. A game changer?
April 23, 2021
https://www.indiatoday.in/coronavir...ne-effective-shows-promise-1794058-2021-04-23
April 1,2021
"A single dose of an experimental COVID-19 vaccine delivered into the nose of rhesus macaques protected their lungs and nasal region from SARS-CoV-2 infection, a new study from National Institutes of Health scientists and colleagues shows. The vaccine, known in its pre-clinical formulation as ChAd-SARS-CoV-2-S, is undergoing clinical trials in India under the name BBV154."
https://www.niaid.nih.gov/news-events/covid-19-nasal-vaccine
Mar. 16, 2021
Finnish academics developing intranasal COVID-19 vaccine
https://www.mobihealthnews.com/news/emea/finnish-academics-developing-intranasal-covid-19-vaccine
Jan. 2021
"In order to be effective, a coronavirus vaccine must provide protection at the site where the virus enters the body, namely the respiratory tract. Neutralizing antibodies present in the blood only contribute partially to protection. The lentiviral vector is now emerging as a promising vaccine candidate for intranasal administration to induce mucosal immunity with an almost sterilizing effect in two highly sensitive preclinical animal models."
Pierre Charneau, Head of the Institut Pasteur Molecular Virology and Vaccinology Unit, Chief Scientific Officer of TheraVectys, Head of the two entities' Joint Lab.
https://www.pasteur.fr/en/press-are...dministration-provides-sterilizing-protection
April 23, 2021
https://www.indiatoday.in/coronavir...ne-effective-shows-promise-1794058-2021-04-23
April 1,2021
"A single dose of an experimental COVID-19 vaccine delivered into the nose of rhesus macaques protected their lungs and nasal region from SARS-CoV-2 infection, a new study from National Institutes of Health scientists and colleagues shows. The vaccine, known in its pre-clinical formulation as ChAd-SARS-CoV-2-S, is undergoing clinical trials in India under the name BBV154."
https://www.niaid.nih.gov/news-events/covid-19-nasal-vaccine
Mar. 16, 2021
Finnish academics developing intranasal COVID-19 vaccine
https://www.mobihealthnews.com/news/emea/finnish-academics-developing-intranasal-covid-19-vaccine
Jan. 2021
"In order to be effective, a coronavirus vaccine must provide protection at the site where the virus enters the body, namely the respiratory tract. Neutralizing antibodies present in the blood only contribute partially to protection. The lentiviral vector is now emerging as a promising vaccine candidate for intranasal administration to induce mucosal immunity with an almost sterilizing effect in two highly sensitive preclinical animal models."
Pierre Charneau, Head of the Institut Pasteur Molecular Virology and Vaccinology Unit, Chief Scientific Officer of TheraVectys, Head of the two entities' Joint Lab.
https://www.pasteur.fr/en/press-are...dministration-provides-sterilizing-protection
